Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach

被引：22

作者：

Sarkadi, Balazs ^{[1
]}

Saskoi, Eva ^{[2
]}

Butz, Henriett ^{[1
,2
,3
]}

Patocs, Attila ^{[1
,2
,3
]}

机构：

[1] ELKH Hereditary Canc Res Grp, H-1052 Budapest, Hungary

[2] Natl Inst Oncol, Dept Mol Genet, H-1122 Budapest, Hungary

[3] Semmelweis Univ, Dept Lab Med, H-1085 Budapest, Hungary

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 03期

关键词：

pheochromocytoma; paraganglioma; hereditary tumor; susceptibility genes; germline; somatic; metastatic; treatment; personalized medicine; RECEPTOR RADIONUCLIDE THERAPY; FUNCTIONAL IMAGING MODALITIES; GERMLINE MUTATIONS; METASTATIC PHEOCHROMOCYTOMA; SPORADIC PHEOCHROMOCYTOMAS; RET PROTOONCOGENE; HIF2A MUTATIONS; MAX MUTATIONS; EXPRESSION; ACTIVATION;

D O I：

10.3390/ijms23031450

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pheochromocytomas and paragangliomas are the most heritable endocrine tumors. In addition to the inherited mutation other driver mutations have also been identified in tumor tissues. All these genetic alterations are clustered in distinct groups which determine the pathomechanisms. Most of these tumors are benign and their surgical removal will resolve patient management. However, 5-15% of them are malignant and therapeutical possibilities for them are limited. This review provides a brief insight about the tumorigenesis associated with pheochromocytomas/paragangliomas in order to present them as potential therapeutical targets.

引用

页数：17

共 50 条

[21] Genetics and the Clinical Approach to Paragangliomas
Schulte, K. -M.
Talat, N.
Galata, G.
Aylwin, S.
Izatt, L.
Eisenhofer, G.
Barthel, A.
Bornstein, S. R.
HORMONE AND METABOLIC RESEARCH, 2014, 46 (13) : 964 - 973
[22] Screening for Pheochromocytomas and Paragangliomas
Eisenhofer, Graeme
CURRENT HYPERTENSION REPORTS, 2012, 14 (02) : 130 - 137
[23] Imaging of pheochromocytomas and paragangliomas
Shern L. Chew
Nature Reviews Endocrinology, 2010, 6 : 193 - 194
[24] Pheochromocytomas and secreting paragangliomas
Pierre-François Plouin
Anne-Paule Gimenez-Roqueplo
Orphanet Journal of Rare Diseases, 1
[25] PET and Pheochromocytomas/Paragangliomas
不详
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (06) : 28N - 28N
[26] Screening for Pheochromocytomas and Paragangliomas
Graeme Eisenhofer
Current Hypertension Reports, 2012, 14 : 130 - 137
[27] Familial pheochromocytomas and paragangliomas
King, Kathryn S.
Pacak, Karel
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 386 (1-2) : 92 - 100
[28] Genotype and tumor location determine gene expression signatures in pseudohypoxic pheochromocytomas and paragangliomas
Fliedner, S. M.
Shankavaram, U.
Elkahloun, A. G.
Huynh, T. T.
Linehan, W. M.
Timmers, H. J.
Tischler, A. S.
Powers, J.
de Krijger, R.
Baysal, B.
David, G.
Lehnert, H.
Camphausen, K.
Pacak, K.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2013, 121 (03)
[29] Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
Manta, Aspasia
Kazanas, Spyridon
Karamaroudis, Stefanos
Gogas, Helen
Ziogas, Dimitrios C.
ONCOLOGY RESEARCH, 2022, 30 (05) : 211 - 219
[30] Biological diagnosis of pheochromocytomas and paragangliomas
d'Herbomez, Michele
Rouaix, Nathalie
Bauters, Catherine
Wemeau, Jean-Louis
PRESSE MEDICALE, 2009, 38 (06): : 927 - 934

← 1 2 3 4 5 →